Off-Label Discussion, But No Additions, For House User Fee Bill

Several Republicans remain interested in expanding off-label communications, suggesting the issue could come up outside the user fee context, potentially as part of future drug pricing discussions.

Updates to the US FDA's off-label communications policy remain a priority for some in the House of Representatives, even though they may not become part of the user fee reauthorization bill.

Members of the House Energy and Commerce Subcommittee on Health promoted two bills that would expand sponsor off-label conversations with...